Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
205.7 EUR | -0.34% | -0.05% | +13.33% |
May. 16 | ESSILORLUXOTTICA : JP Morgan maintains a Buy rating | ZD |
May. 07 | CAC40: gains altitude, banking sector in support | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 34.72 and 30.43 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.71 times its current sales, is high.
- The company is highly valued given the cash flows generated by its activity.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.33% | 101B | B | ||
+22.43% | 44.19B | B | ||
+3.48% | 19.46B | B- | ||
-17.76% | 2.31B | D+ | ||
+14.54% | 1.92B | C+ | ||
+28.37% | 1.23B | - | ||
-35.09% | 755M | - | ||
-40.97% | 699M | B- | ||
-7.22% | 677M | - | ||
+26.26% | 510M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EL Stock
- Ratings EssilorLuxottica